Moreover, 2 patients with concurrent EML4-ALK and EGFR mutations had superior PFS after EGFR-TKI compared to patients with single EML4-ALK rearrangement.     ///    Patients with stage IV NSCLC were screened for EML4-ALK rearrangement and EGFR mutations at the Peking University Cancer Hospital.     ///    EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer..     ///    Response to EGFR-tyrosine kinase inhibitor (TKI) was similar between patients with EML4-ALK rearrangement and EGFR mutation (33.3 vs.     ///    EML4-ALK was identified using fluorescent in situ hybridization and confirmed by immunohistochemistry.     ///    Patients with EML4-ALK were more likely to present the EGFR wild type (WT.     ///    Patients with EML4-ALK conferred similar objective response rates after EGFR-TKI although inferior PFS compared to those with EGFR mutation.     ///    Coexistence of EML4-ALK and EGFR mutation might represent a separate NSCLC genotype..     ///    The incidence of EML4-ALK was 9.7% (11/113).     ///    Patients with EML4-ALK were more likely to present the EGFR wild type (WT; p = 0.033).